Stockreport

ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle [Seeking Alpha]

ImmunityBio, Inc.  (IBRX) 
PDF Anktiva faces tough competition from existing treatments and promising therapies in the pipeline. ImmunityBio has financial resources for the short-term, but long-ter [Read more]